Teva Pharmaceutical Industries Ltd (NYSE:TEVA) Position Cut by Meag Munich Ergo Kapitalanlagegesellschaft MBH

Meag Munich Ergo Kapitalanlagegesellschaft MBH decreased its position in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 83.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,000 shares of the company’s stock after selling 25,000 shares during the period. Meag Munich Ergo Kapitalanlagegesellschaft MBH’s holdings in Teva Pharmaceutical Industries were worth $78,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the company. FMR LLC raised its stake in shares of Teva Pharmaceutical Industries by 44.0% during the fourth quarter. FMR LLC now owns 35,248,665 shares of the company’s stock valued at $543,534,000 after acquiring an additional 10,766,729 shares in the last quarter. Norges Bank bought a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter valued at approximately $146,130,000. Brahman Capital Corp. raised its stake in shares of Teva Pharmaceutical Industries by 67.3% during the fourth quarter. Brahman Capital Corp. now owns 12,248,106 shares of the company’s stock valued at $188,866,000 after acquiring an additional 4,925,245 shares in the last quarter. Menora Mivtachim Holdings LTD. increased its holdings in Teva Pharmaceutical Industries by 6,156.1% during the fourth quarter. Menora Mivtachim Holdings LTD. now owns 3,658,479 shares of the company’s stock valued at $56,414,000 after buying an additional 3,600,000 shares during the period. Finally, Harel Insurance Investments & Financial Services Ltd. increased its holdings in Teva Pharmaceutical Industries by 99.9% during the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 5,715,499 shares of the company’s stock valued at $88,133,000 after buying an additional 2,855,802 shares during the period. Hedge funds and other institutional investors own 65.12% of the company’s stock.

Shares of TEVA traded up $0.18 during mid-day trading on Wednesday, hitting $9.70. 34,542,625 shares of the company were exchanged, compared to its average volume of 16,146,155. Teva Pharmaceutical Industries Ltd has a 1-year low of $11.26 and a 1-year high of $25.96. The company has a quick ratio of 0.62, a current ratio of 0.96 and a debt-to-equity ratio of 1.66. The company has a market cap of $11.05 billion, a PE ratio of 3.46, a price-to-earnings-growth ratio of 1.37 and a beta of 1.30.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Thursday, May 2nd. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 18.66% and a positive return on equity of 16.84%. The firm had revenue of $4.30 billion during the quarter, compared to the consensus estimate of $4.38 billion. During the same quarter in the prior year, the firm earned $0.94 EPS. The company’s revenue for the quarter was down 15.2% on a year-over-year basis. As a group, sell-side analysts expect that Teva Pharmaceutical Industries Ltd will post 2.26 earnings per share for the current year.

In other news, insider Deborah A. Griffin sold 4,107 shares of the stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $16.88, for a total value of $69,326.16. Following the completion of the sale, the insider now owns 2,941 shares of the company’s stock, valued at approximately $49,644.08. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Richard Daniell sold 2,098 shares of the stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $16.88, for a total transaction of $35,414.24. Following the completion of the sale, the vice president now directly owns 2,098 shares of the company’s stock, valued at approximately $35,414.24. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 28,349 shares of company stock valued at $384,241. 0.49% of the stock is owned by corporate insiders.

Several brokerages recently issued reports on TEVA. Bank of America reissued a “buy” rating and set a $24.00 price objective on shares of Teva Pharmaceutical Industries in a report on Tuesday, February 5th. HSBC set a $12.00 price objective on shares of Teva Pharmaceutical Industries and gave the company a “sell” rating in a report on Tuesday, February 5th. Credit Suisse Group reaffirmed a “hold” rating and issued a $26.00 price target on shares of Teva Pharmaceutical Industries in a report on Tuesday, February 5th. Oppenheimer reaffirmed a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Monday, February 11th. Finally, Mizuho lowered shares of Teva Pharmaceutical Industries from a “buy” rating to a “neutral” rating and cut their price target for the stock from $25.00 to $18.00 in a report on Wednesday, February 20th. Three equities research analysts have rated the stock with a sell rating, seventeen have issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $20.00.

WARNING: “Teva Pharmaceutical Industries Ltd (NYSE:TEVA) Position Cut by Meag Munich Ergo Kapitalanlagegesellschaft MBH” was originally published by Sundance Herald and is the property of of Sundance Herald. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://sundanceherald.com/2019/05/29/teva-pharmaceutical-industries-ltd-teva-position-cut-by-meag-munich-ergo-kapitalanlagegesellschaft-mbh.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Featured Article: Using other technical indicators with support levels

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply